New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
17:41 EDTBHI, WLL, VRX, WFT, HESPoint72 Asset Management gives quarterly update on stakes
NEW STAKES: Baker Hughes (BHI), Whiting Petroleum (WLL), Valeant (VRX), Weatherford (WFT), and Hess (HES).
News For BHI;WLL;VRX;WFT;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 15, 2014
09:07 EDTBHIBaker Hughes upgraded at Sterne Agee
Subscribe for More Information
07:44 EDTHESHess volatility at five-year highs as oil trends below $81
Subscribe for More Information
07:11 EDTWFTWeatherford initiated with a Buy at ISI Group
Target $29.
07:11 EDTBHIBaker Hughes initiated with a Buy at ISI Group
Subscribe for More Information
06:45 EDTBHIBaker Hughes upgraded to Buy from Neutral at Sterne Agee
Subscribe for More Information
06:32 EDTBHI, WFTCiti rolls out Oil Services coverage, recommends two pair trades
Subscribe for More Information
06:11 EDTWFTWeatherford initiated with a Neutral at Citigroup
Subscribe for More Information
06:07 EDTBHIBaker Hughes initiated with a Buy at Citigroup
Subscribe for More Information
October 10, 2014
13:03 EDTBHIBaker Hughes reports U.S. rig count up 8 to 1930
Subscribe for More Information
10:05 EDTHESHess calls active on renewed takeover chatter
Hess October 84 and 85 calls area active on total call volume of 2,700 contracts (300 puts) on renewed takeover chatter. October call option implied volatility is at 37, November is at 32, December is at 30, January is at 27; compared to its 26-week average of 20 according to Track Data. Active call volume suggests traders taking positions for large price movement.
10:01 EDTWFTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:55 EDTHESRumor: Hess Corp. moves up on renewed takeover chatter
Subscribe for More Information
09:20 EDTWLLWhiting Petroleum volatility spikes, share and energy prices trend lower
Whiting Petroleum overall option implied volatility of 46 compares to its 26-week average of 32 according to Track Data, suggesting large near term price movement.
07:37 EDTVRXActavis more likely partner than Valeant if Allergan merges, says UBS
Subscribe for More Information
07:16 EDTVRXAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
05:53 EDTWFTWeatherford upgraded to Buy from Hold at Societe Generale
Societe Generale upgraded Weatherford to Buy with a $24 price target.
October 9, 2014
14:21 EDTVRXAllergan in good position to be patient given raised outlook, says BMO Capital
After speaking with Allergan's (AGN) CEO and CFO, BMO Capital believes the company is increasing its intrinsic value with its raised earnings guidance and that it is in a good position to be patient given that Valeant (VRX) most recent bid represents an 8% discount to Allergan's current share price. BMO said it is reviewing its forecasts for Allergan after the guidance increase, noting that it previously valued Allergan at $230 per share on a standalone basis. The firm maintains its Outperform rating on the stock.
12:28 EDTVRXAllergan price target raised to $230 from $210 at BTIG
BTIG said it expected Allergan to beat the consensus forecast for Q3 EPS, but not by as much as it did, and the firm did not expect the company to raise its future EPS outlook yet again. BTIG feels the stock's move higher indicates Valeant (VRX) or Actavis (ACT) would need to bid above $200 if they hope to buy the company. BTIG maintains its Buy rating on Allergan and raised its price target on the stock to $230 from $210.
11:14 EDTVRXAllergan raises outlook again as Valeant pursuit continues
Drug maker Allergan (AGN) this morning preannounced stronger than expected results and again raised its fiscal year profit guidance. The beat and raise results come after The Wall Street Journal reported on Tuesday that drug maker Valeant (VRX) and hedge fund Pershing Square intend to raise their previous bid for Allergan by $15 per share to about $191. Meanwhile, also on Tuesday, Reuters said that drug maker Actavis (ACT) plans to make a new merger offer to Allergan, and sources indicated to the news service that Allergan may be willing to consider an offer from Actavis if the bid is for more than $200 per share. WHAT'S NEW: Allergan estimated that its third quarter earnings per share would come in at $1.76-$1.78, versus analysts' consensus estimate of $1.48. The drug maker had previously provided Q3 EPS guidance of $1.44-$1.47. Allergan raised its fiscal 2014 EPS guidance to $6.20-$6.25 from $5.74-$5.80. Analysts' consensus estimate was $5.81. This is the fourth time that Allergan has raised its guidance this year. Allergan said that its markets have been strong around the world, while it is gaining market share in most categories. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that, in the wake of Allergan's guidance increase, the company's price to earnings multiple could expand to 22x its estimated 2016 earnings, up from its current multiple of 19x. In addition to the raised guidance, a potential accretive acquisition by Allergan and the possibility that it will be acquired make such an increase in the multiple "quite possible," Biegelsen contended. He kept an Outperform rating on the stock. WHAT'S NOTABLE: Allergan has reportedly held advanced talks about acquiring another company in the sector, Salix (SLXP), although CNBC's David Faber on October 2 reported that the talks between the two companies about a merger had "cooled considerably." PRICE ACTION: In late morning trading, Allergan rose fractionally to $191.06 while Valeant slid 1.5% to $124.08.
08:50 EDTVRXAllergan shares have further upside, says Wells Fargo
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use